Competitive Rivalry

INMB competes in immunology and inflammation with large-cap biopharma peers that have broader pipelines and commercial scale, limiting its ability to defend pricing or share.

Because the company remains development-stage relative to global peers, rivalry is shaped by data readouts and partnering leverage rather than durable product differentiation.

The absence of a diversified marketed franchise leaves INMB more exposed to competitive pipeline resets than peers with multiple approved assets and cash-generating products.

Threat Of New Entrants

High capital requirements, long development timelines, and regulatory hurdles make entry difficult, so INMB benefits from the same structural barriers that protect established biotech peers.

Scientific and clinical validation requirements reduce the likelihood of fast followers eroding economics, supporting industry-wide scarcity value for differentiated immunology assets.

However, platform-based entrants and large pharma internal R&D can still target the same therapeutic space, so barriers are meaningful but not absolute versus peers.

Bargaining Power Of Suppliers

Specialized CROs, CDMOs, and clinical vendors can exert pricing pressure on small biotechs like INMB, but this is partly offset by outsourced, competitive procurement markets.

Compared with larger peers, INMB has less volume leverage and fewer alternate internal capabilities, which can raise trial and manufacturing costs per program.

Supplier power is constrained by the availability of multiple service providers, so margin pressure is real but not structurally severe versus the broader biotech peer set.

Bargaining Power Of Buyers

INMB has limited direct buyer power today because it lacks a broad commercial product base, so payer and provider negotiations do not yet support durable pricing power.

If approved, concentrated U.S. payers and hospital systems would likely pressure launch pricing more than for niche peers with stronger clinical differentiation or orphan positioning.

Relative to global biopharma peers with established brands and formularies, INMB would face weaker reimbursement leverage and more discounting risk at commercialization.

Threat Of Substitutes

Existing biologics, small molecules, and standard-of-care regimens create meaningful substitution risk in inflammatory disease, limiting any future pricing premium for INMB.

Because physicians can often switch among mechanistically similar therapies, substitute pressure is stronger than for peers with first-in-class or biomarker-defined franchises.

The substitute threat remains structurally high until INMB demonstrates clear clinical differentiation that would justify sustained reimbursement and margin protection.

Overall Score

INMB’s industry structure is unfavorable versus global biopharma peers because rivalry and substitutes are intense, buyer power would be high at commercialization, and supplier leverage remains a cost headwind.